glp-1 and prostate cancer Targeting obesity, metabolic syndrome, cancer: agonists as emerging therapeutic agents | Discover Oncology Risk of pancreatic cancer associated

Sed dui velit, tincidunt quis neque quis, laoreet pellentesque justo

Evidence suggests GLP-1 medications can reduce inflammation, pain, and disease activity in several forms of arthritis, especially when obesity or insulin resistance is also present

Ocaliva, a farsenoid X receptor agonist, won the FDAs accelerated approval for PBC in May 2016

The demonstrated success with liraglutide, a commercially significant peptide therapeutic, makes this particularly relevant for organizations considering their manufacturing strategy in the growing GLP-1 market

Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, et al

Polygenic Risk Score (PRS) estimates your lifetime risk for major conditions like heart disease, stroke, diabetes, Alzheimers, osteoporosis, and several cancers (including breast, prostate, and ovarian)